A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DM
Active not recruiting
The purpose of this study is to:
* evaluate the safety and tolerability of single ascending doses of ALN-4324 in healthy volunteers and to characterize the single-dose PK of ALN-4324
* evaluate the efficacy, safety, tolerability, PK, and pharmacodynamics (PD) of multiple doses of ALN-4324 in adult overweight to obese patients with T2DM
Trial at a Glance
- Trial ID
- ALN-4324-001
- Condition
- Type 2 Diabetes Mellitus (T2DM), Obese or Overweight Healthy Volunteers
- Drug/Treatment
- Placebo, ALN-4324
- Does this trial use a placebo?
- Yes
- Trial Type
- Interventional
- Number of Participants
- 105 participants
- Trial dates
- 2025-03-03 - 2027-08-31
For more information:NCT06845202
Who can participate?
AGE
18 to 75 Years
SEX
All
ACCEPTS HEALTHY VOLUNTEERS?
Yes
Inquire about a clinical trial
Contact Alnylam directly with any questions about our clinical trials.
Inquire about a clinical trial
Contact Alnylam directly with any questions
about our clinical trials.
about our clinical trials.
